Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. (XAIR) has filed a resale prospectus covering up to 5,417,538 shares of common stock that may be offered from time to time by selling stockholders. The registered shares consist of 167,011 outstanding shares plus shares issuable upon exercise of pre-funded, Series A and Series B warrants issued in a July 29, 2026 private placement.
Beyond Air is not selling shares in this offering and will not receive proceeds from resales, though it will receive cash if warrants are exercised. The July 31, 2026 private placement raised ~$10.2 million in gross proceeds at combined prices of $5.66–$5.76 per share (or pre-funded warrant) plus common warrants.
The company recently effected a 1-for-20 reverse stock split effective July 13, 2026 to regain Nasdaq bid-price compliance; it is now under a one-year Nasdaq discretionary panel monitor, and future listing deficiencies during this period could lead to an accelerated delisting process. Common shares outstanding were 755,549 as of July 28, 2026 and would be 6,173,087 if all new warrants are fully exercised.
Beyond Air, Inc. (XAIR) reported results for the quarter ended June 30, 2026 and provided a corporate update. Revenue was $1.8 million, roughly flat year over year, while gross margin improved to 13% from 9%. Net loss attributable to common stockholders was $7.9 million, or $11.00 per share, compared with a loss of $7.7 million, or $30.67 per share, a year earlier.
As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $15.2 million, against $22.2 million of long-term debt and total liabilities of $30.1 million, leaving stockholders’ equity at $2.8 million. After quarter-end, the company completed an up to $30.1 million financing, including $10.2 million in upfront gross proceeds and up to an additional $20.0 million from potential warrant exercises. Management reaffirmed revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, and highlighted ongoing FDA review of a PMA supplement for its second-generation LungFit PH system, with approval expected in the second half of 2026.
Beyond Air, Inc. is registering for resale up to 5,417,538 shares of common stock for selling stockholders. The Shares consist of 167,011 issued shares plus shares issuable from Pre-Funded, Series A, and Series B Warrants. Beyond Air is not selling shares in this offering and will not receive proceeds from resales, though it may receive cash if warrants are exercised, which it expects to use for general working capital.
The Shares stem from a July 29, 2026 securities purchase agreement and a July 31, 2026 private placement that generated $10.2 million in gross proceeds at prices near market. Pre-Funded Warrants are exercisable at $0.0001 per share; Series A and B Warrants at $5.51 per share, subject to 4.99%–19.99% beneficial ownership limits. Common stock outstanding was 755,549 shares as of July 28, 2026, and would be 6,173,087 shares if all new warrants are exercised.
The company completed a 1-for-20 reverse stock split effective July 13, 2026 to address prior Nasdaq bid-price noncompliance and is now under a one-year Discretionary Panel Monitor. Beyond Air is a commercial-stage company marketing its FDA- and CE-marked LungFit® PH nitric oxide system and developing additional NO-based respiratory, oncology and neurology programs.
Balyasny Asset Management and related entities report a significant ownership position in Beyond Air, Inc. The group, including Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, is deemed to beneficially own 763,266 shares of Beyond Air common stock, including 299,104 shares issuable upon exercise of Warrants.
This position represents 5.30% of the outstanding common stock, based on 14,410,621 shares outstanding as of June 26, 20269.99% Beneficial Ownership Limitation, which blocks exercises that would push ownership above that threshold. The shares are held for the benefit of Atlas Diversified Master Fund, Ltd., a Cayman Islands exempted company advised by Balyasny.
Beyond Air, Inc. reported another quarterly loss and highlighted serious liquidity risk for the three months ended June 30, 2026. Revenue was essentially flat at $1.8 million, while cost of revenues was $1.5 million, yielding modest gross profit of $0.2 million. Operating expenses remained high at $6.8 million, driven mainly by selling, general and administrative costs, resulting in a loss from operations of $6.6 million and a net loss attributable to Beyond Air of $7.9 million.
Cash used in operating activities was $4.9 million. Cash, cash equivalents, marketable securities and restricted cash totaled $15.2 million, including $5.4 million of restricted cash, against long-term debt of $22.2 million. Management stated that recurring losses, limited cash resources and expected cash outflows raise substantial doubt about the ability to meet obligations within one year without additional financing. During the quarter the company converted $0.5 million of promissory note principal into equity, exercised 95,000 pre-funded warrants, and completed a 1‑for‑20 reverse stock split. After quarter-end it raised $10.2 million gross in a private placement with attached warrants.
Beyond Air, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement after implementing a 1-for-20 reverse stock split of its common stock on July 13, 2026.
Nasdaq confirmed compliance in an August 6, 2026 letter, based on the company’s common stock maintaining a closing bid of at least $1.00 per share for 17 consecutive trading days from July 13 through August 4, 2026. This also satisfies conditions previously set by a Nasdaq Hearings Panel for continued listing on The Nasdaq Capital Market.
The Panel imposed a Discretionary Panel Monitor for one year from the compliance letter. During this monitor period, any failure to meet a Nasdaq continued listing requirement will result in an immediate delisting determination, without the opportunity to submit a compliance plan or obtain additional time from Nasdaq staff; any appeal would go directly to the Hearings Panel.
Beyond Air, Inc. Chief Executive Officer Robert Scott Goodman purchased 34,722 shares of common stock on July 29, 2026 at $5.76 per share, bringing his direct common stock holdings to 34,822 shares. He also acquired 34,722 Series A Warrants and 34,722 Series B Warrants, each exercisable for common stock at $5.51 per share. The warrants are exercisable immediately; the Series A Warrants expire on the earlier of one year after issuance or 45 days following FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance.
Beyond Air, Inc. Chief Financial Officer Daniel J. Moorhead reported purchases on 2026-07-29 of 4,340 shares of common stock at $5.76 per share, along with 4,340 Series A Warrants and 4,340 Series B Warrants, each exercisable for common stock at $5.51 per share. The Series A Warrants are exercisable immediately and expire on the earlier of one year from issuance or 45 days after FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance. Following these transactions, Moorhead holds 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants directly.
Beyond Air, Inc. entered into a private placement with institutional investors and insiders to raise approximately $10.2 million in upfront gross proceeds. The company will issue 167,011 common shares and pre-funded warrants for up to 1,638,835 shares, each paired with Series A and Series B common stock warrants.
The warrants cover up to 1,805,846 shares each for Series A and Series B at a $5.51 exercise price, contributing to potential aggregate proceeds of up to $30.1 million if fully exercised for cash. Pre-funded warrants are exercisable at $0.0001, subject to 19.99% ownership caps; other warrants have 9.99% caps, with expirations tied to FDA action on LungFit PH II or five years after issuance. Net proceeds are intended for working capital and general corporate purposes, and the company agreed to resale registration and temporary limitations on new equity issuances.